At a glance
ClinicalIndex Comparison RecordPhase 2Unknown· 33 enrolled
Drug / intervention
Cisplatin/Capecitabinedrug
Likely dose
Cisplatin/Capecitabine 1000mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Capecitabine and Cisplatin in Anthracycline and Taxanes-pretreated Metastatic Triple Negative Breast Cancer Patients
In Brief
A Phase 2 clinical trial evaluating Cisplatin/Capecitabine for Metastatic Breast Cancer. Targeting 33 participants across 1 site.
Detailed Summary
It is a phase II trial to explore the efficacy and safety of cisplatin plus capecitabine in anthracycline and taxane-pretreated metastatic triple negative breast cancer patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Breast Cancer
CountriesChina
Collaborators--
Timeline
Phase 2UnknownOverdue
20132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2012
First PostedAug 2013
Primary CompletionOct 2015
Study CompletionMar 2016
TodayJul 2026
First PostedAug 27, 2013
Enrollment StartNov 1, 2012
Primary CompletionOct 1, 2015
Study CompletionMar 1, 2016
TodayJul 1, 2026
Enrollment to primary: 2.9 yearsPosted 12.8 years ago
Interventions
Cisplatin/Capecitabinedrug
Cisplatin/Capecitabine: Capecitabine 1000mg/m2 orally Bid on day 1 to day 14 plus Cisplatin 75mg/m2 on day1 of each 21 day cycle, until progression or untolerable toxicity